Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Adjuvant Pembrolizumab Prolongs DFS Regardless of PD-L1 or Nodal Status in High-Risk MIBC

September 25th 2024

Adjuvant pembrolizumab generated a DFS benefit vs observation in patients with high-risk muscle-invasive bladder cancer after radical surgery.

BL-B01D1 Shows Preliminary Efficacy, Safety in Pretreated Advanced Urothelial Carcinoma

September 24th 2024

BL-B01D1 displayed safety and preliminary efficacy in previously treated locally advanced or metastatic urothelial carcinoma.

Frontline Enfortumab Vedotin Plus Pembrolizumab Receives Approval in Japan for Unresectable Urothelial Carcinoma

September 24th 2024

Enfortumab vedotin plus pembrolizumab has been approved in Japan for first-line radically unresectable urothelial carcinoma.

QOL Benefits With Nivolumab, Challenges with Sacituzumab Govitecan Characterize Bladder Cancer Management Updates

September 23rd 2024

Guru Sonpavde, MD, expands on findings from 2 key bladder cancer trials presented at the 2024 ESMO Congress.

Dr Ye on Early Efficacy Data for BL-B01D1 in Metastatic Urothelial Carcinoma

September 20th 2024

Dingwei Ye, MD, PhD, discusses the initial efficacy and safety of BL-B01D1 in locally advanced or metastatic urothelial carcinoma.

Dr Ye on the Safety and Efficacy of BL-B01D1 in Locally Advanced/Metastatic Urothelial Carcinoma

September 17th 2024

Dingwei Ye, MD, PhD, discusses the safety and efficacy outcomes of a clinical trial evaluating BL-B01D1 in locally advanced or metastatic urothelial carcinoma.

Neoadjuvant TAR-200/Cetrelimab Combo Shows Activity in Muscle-Invasive Bladder Cancer

September 16th 2024

Neoadjuvant TAR-200 plus cetrelimab elicited responses and was safe in muscle-invasive bladder cancer.

Dr Friedlander on AEs Associated With Enfortumab Vedotin in Bladder Cancer

September 16th 2024

Terence W. Friedlander, MD, discusses adverse effects that are associated with standard enfortumab vedotin in bladder cancer.

Addition of Perioperative Durvalumab to Neoadjuvant Chemo Generates Survival Benefits in Cisplatin-Eligible MIBC

September 15th 2024

NIAGARA was the first phase 3 study to evaluate perioperative immunotherapy plus neoadjuvant chemotherapy in cisplatin-eligible muscle-invasive bladder cancer.

utDNA Could Provide Noninvasive Tool for MRD Detection Prior to Repeat TURBT in High-Risk NMIBC

September 13th 2024

Joshua Linscott, MD, PhD, discusses the use of urinary cell-free tumor DNA for MRD detection prior to repeat resection in high-risk NMIBC.

Dr Linscott on the Use of Urinary Cell-free Tumor DNA to Predict MRD in High-Risk NMIBC

September 10th 2024

Joshua Linscott, MD, PhD, discusses the use of utDNA to predict MRD prior to repeat TURBT in patients with high-risk non-muscle invasive bladder cancer.

Dr Friedlander on Updates in Frontline Bladder Cancer Management

September 9th 2024

Terence W. Friedlander, MD, discusses updates in the frontline management of bladder cancer.

Dr Bochner on the Need for Multimodal Approaches in MIBC

September 4th 2024

Bernard H. Bochner, MD, FACS discusses genomic complexity and heterogeneity in bladder cancer tumors.

Dr Li on Safety Data Derived From the CORE-001 Trial in BCG-Unresponsive NMIBC

August 30th 2024

Roger Li, MD, discusses safety data from the final analysis of the CORE-001 trial in BCG-unresponsive non–muscle-invasive bladder cancer.

Dr Li on Cretostimogene Grenadenorepvec Plus Pembrolizumab in BCG-Unresponsive NMIBC

August 29th 2024

Roger Li, MD, discusses the final analysis of the CORE-001 trial of cretostimogene grenadenorepvec plus pembrolizumab in BCG-unresponsive NMIBC with CIS.

Enfortumab Vedotin Plus Pembrolizumab Approved in Europe for Metastatic Urothelial Cancer

August 28th 2024

The European Commission granted marketing authorization to frontline enfortumab vedotin plus pembrolizumab for unresectable/metastatic urothelial cancer.

Dr Cigliola on Potential Implications of the SURE-01 and SURE-02 Trials in MIBC

August 27th 2024

Antonio Cigliola, MD, discusses potential clinical implications of data from the phase 2 SURE-01 and SURE-02 trials in MIBC.

Dr Linscott on the Need for Improved MRD Detection in High-Risk NMIBC

August 23rd 2024

Joshua Linscott, MD, PhD, discusses a study evaluating a utDNA assay for minimal residual disease detection in patients with high-risk NMIBC.

Erdafitinib Wins EU Approval for FGFR3+ Unresectable, Metastatic Urothelial Carcinoma

August 23rd 2024

Erdafitinib was approved by the European Commission for pretreated unresectable or metastatic urothelial carcinoma harboring FGFR3 alterations.

Dr Nawfal on the Rationale for Assessing Radiological Tumor Burden in mccRCC

August 23rd 2024

Rashad Nawfal, MD, discusses radiological tumor burden as an independent prognostic factor for survival in metastatic clear cell renal cell carcinoma.